Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Recruiting 3Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 18Breast Neoplasms 11Ovarian Neoplasms 10Uterine Cervical Neoplasms 6Carcinoma, Ovarian Epithelial 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 4Neoplasm Metastasis 4Central Nervous System Neoplasms 4Esophageal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Retinoblastoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Inflammatory Breast Neoplasms 2Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thoracic Neoplasms 1Salivary Gland Neoplasms 1

Interventions

necitumumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Respiratory Tract Diseases × Carboplatin × Clear all
NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Withdrawn
Thoracic

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡